Methods and composition of treating a flaviviridae family viral infection

US9101628B2 · kind B2 · utility

Assignee

• The Board of Trustees of the Leland Stanford Junior University · US

Inventors

• Shirit Einav · Stanford, US
• Jeffrey S. Glenn · Palo Alto, US
• Wenjin Yang · Foster City, US
• Hadas Dvory-Sobol · Mountain View, US
• Ingrid Choong · Palo Alto, US
• Robert McDowell · San Francisco, US

Key dates

• Filing date: Mar 18, 2009
• Grant date: Aug 11, 2015
• Expiry date: Jul 23, 2030

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like. In an embodiment, the compounds can include clemizole or a clemizole analog, or a pharmaceutically acceptable salt, an isomer, a tautomer, or a prodrug thereof.